Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus A Andersen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Neuroscience Methods|June 1, 2014
Brain penetration assessment in vivo: a reliable and simple method in anesthetized rats at steady stateClaus A Andersen, Paolo Perfetti, Martina Nibbio, et al.
BMC Bioinformatics|May 13, 2009
Robust MS quantification method for phospho-peptides using 18O/16O labelingClaus A Andersen, Stefano Gotta, Letizia Magnoni, et al.
British Journal of Clinical Pharmacology|September 17, 2014
Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteersGoran Westerberg, Joseph A Chiesa, Claus A Andersen, et al.
Frontiers in Medicine|July 26, 2024
Interactive medical and safety monitoring in clinical trials with clinDataReview: a validated and open-source reporting toolLaure Cougnaud, Margaux Faes, Dirk Van Krunckelsven, et al.
Frontiers in Immunology|October 2, 2019
Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-ActionPaul R Buckley, Kieran Alden, Margherita Coccia, et al.
Neurobiology of Disease|June 24, 2008
Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicityGiuseppe Pollio, Jeroen J M Hoozemans, Claus A Andersen, et al.
ERJ Open Research|February 18, 2026
Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trialsMatthew J Randall, Claus A Andersen, Kevin K Brown, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Neuroscience Methods|June 1, 2014
Brain penetration assessment in vivo: a reliable and simple method in anesthetized rats at steady stateClaus A Andersen, Paolo Perfetti, Martina Nibbio, et al.
BMC Bioinformatics|May 13, 2009
Robust MS quantification method for phospho-peptides using 18O/16O labelingClaus A Andersen, Stefano Gotta, Letizia Magnoni, et al.
British Journal of Clinical Pharmacology|September 17, 2014
Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteersGoran Westerberg, Joseph A Chiesa, Claus A Andersen, et al.
Frontiers in Medicine|July 26, 2024
Interactive medical and safety monitoring in clinical trials with clinDataReview: a validated and open-source reporting toolLaure Cougnaud, Margaux Faes, Dirk Van Krunckelsven, et al.
Frontiers in Immunology|October 2, 2019
Application of Modeling Approaches to Explore Vaccine Adjuvant Mode-of-ActionPaul R Buckley, Kieran Alden, Margherita Coccia, et al.
Neurobiology of Disease|June 24, 2008
Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicityGiuseppe Pollio, Jeroen J M Hoozemans, Claus A Andersen, et al.
ERJ Open Research|February 18, 2026
Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trialsMatthew J Randall, Claus A Andersen, Kevin K Brown, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Pageof 1